Physician profile
Patrick William Clyde
NPI 1538254941
$824.02
in general payments reported to CMS, 2019-2025
14 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.66 · 2020: $167 · 2021: $247 · 2022: $98.16 · 2023: $88.03 · 2024: $29.37 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $271.61 | 2020-2025 | Sogroya |
| Astrazeneca Pharmaceuticals LP | $215.31 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $76.27 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Glaxosmithkline, LLC. | $42.15 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $35.36 | 2022 | |
| Medtronic, INC. | $31.78 | 2024-2025 | Minimed 780g |
| Beta Bionics, INC. | $30.46 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Insulet Corporation | $29.40 | 2025 | Omnipod |
| Nestle Healthcare Nutrition INC. | $23.19 | 2021 | |
| Opko Pharmaceuticals, LLC | $17.17 | 2021 | |
| Abbott Laboratories | $13.79 | 2021 | |
| Amarin Pharma, INC. | $13.16 | 2021 | |
| Medtronic Minimed, INC. | $12.66 | 2019 | |
| Lilly USA, LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Clyde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.